LTZ Therapeutics
Develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $40.0m Valuation: $400m | Series A | |
| Total Funding | 000k | ||
Related Content
LTZ Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary Myeloid Engager Platform is designed to activate and enhance the function of myeloid cells, a type of immune cell, to generate a robust and durable anti-tumor response.
LTZ's lead product candidate, LTX-001, is a monoclonal antibody that targets a specific receptor on myeloid cells and is currently in Phase 1 clinical trials for the treatment of solid tumors. The company is also developing a pipeline of other myeloid engager candidates for various cancer indications and autoimmune diseases. With operations in both the United States and China, LTZ Therapeutics is strategically positioned to access global talent and resources to advance its innovative pipeline.
Keywords: immunotherapy, oncology, autoimmune diseases, myeloid engager, monoclonal antibody, clinical-stage, biopharmaceutical, cancer treatment, solid tumors, drug development